Research Topics
| Andrew D GoodmanSummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesionsAndrew D Goodman
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
J Infect Dis 187:1365-76. 2003....
Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy)Andrew D Goodman
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Neurotherapeutics 10:106-10. 2013..The exact mechanism of action is uncertain, as is the reason for response variability. The medication serves as proof-of-concept that targeting axonal transmission can improve disability in multiple sclerosis...
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Ann Neurol 68:494-502. 2010..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...- Dalfampridine in multiple sclerosisA D Goodman
Department of Neurology, University of Rochester, Medical Center, Rochester, New York 14642, USA
Drugs Today (Barc) 46:635-9. 2010..The safety profile of dalfampridine is also reviewed, with a focus on the risk for epileptic seizures as an adverse effect... - GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled studyA D Goodman
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Neurology 72:806-12. 2009..The primary outcome assessed whether this combination would increase the rate of development of new active lesions on cranial MRI scans vs GA alone... - Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman
Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
Neurology 71:1134-41. 2008..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)... - Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman
University of Rochester, Rochester, NY, USA
Lancet 373:732-8. 2009..This phase III study assessed efficacy and safety of oral, sustained-release fampridine in people with ambulatory deficits due to multiple sclerosis... - A randomized trial of memantine as treatment for spasticity in multiple sclerosisLahar R Mehta
Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Mult Scler 16:248-51. 2010..The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study... - Symptomatic management in multiple sclerosisLawrence M Samkoff
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Neurol Clin 29:449-63. 2011..This article reviews strategies of symptom management in patients with MS... - Cognitive fatigue during a test requiring sustained attention: a pilot studySteven R Schwid
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Mult Scler 9:503-8. 2003..Motor fatigue can be objectively measured as the decline in strength occurring during sustained contractions. Analogous declines in cognitive performance occur during tasks requiring sustained attention... - Neuropsychologic status in multiple sclerosis after treatment with glatiramerA Weinstein
Department of Neurology, University of Rochester Medical Center, NY 14642, USA
Arch Neurol 56:319-24. 1999..Glatiramer acetate (Copaxone) therapy reduces clinical disease activity in relapsing-remitting multiple sclerosis (MS)... - Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging studyA D Goodman
Department of Neurology, University of Rochester, Rochester, NY 14642, USA rmc rochester edu
Mult Scler 13:357-68. 2007..To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg twice daily... - Quantitative functional measures in MS: what is a reliable change?S R Schwid
Department of Neurology, University of Rochester Medical Center, NY, USA
Neurology 58:1294-6. 2002..Therefore, a 20% change on these tests can be considered to be the threshold that reliably indicates a true change in function for an individual... - Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis ConsortiumIlya Kister
Multiple Sclerosis Care Center, Department of Neurology, New York University School of Medicine, NYU Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003 3804, USA
Mult Scler 17:725-33. 2011..Although the natural history of multiple sclerosis has been charted extensively, it is still not known whether the trajectory of disability accumulation has changed in the era of disease-modifying therapies (DMTs)... - Broadening the spectrum of controls for skin biopsy in painful neuropathiesDavid N Herrmann
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Muscle Nerve 42:436-8. 2010..Distal-leg ENFD/morphology in MS DLLBP patients did not differ significantly from that of healthy controls. This study extends the range of ENFD controls and further supports use of ENFD assessment in SFSN... - Rapid disease course in African Americans with multiple sclerosisI Kister
Department of Neurology, NYU School of Medicine, Multiple Sclerosis Care Center, New York, NY 10003 3804, USA
Neurology 75:217-23. 2010..MSSS is a frequency-rank algorithm relating MS disability to disease duration in a large, untreated reference population. Design/.. - Assessment of JC virus DNA in blood and urine from natalizumab-treated patientsRichard A Rudick
Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Ann Neurol 68:304-10. 2010..Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab-treated multiple sclerosis (MS) patients to predict the risk of progressive multifocal leukoencephalopathy (PML)... - Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndromeLahar R Mehta
Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Mult Scler 14:425-7. 2008.... - Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trialSteven R Schwid
University of Rochester, Department of Neurology, Rochester, NY 14642, USA
J Neurol Sci 255:57-63. 2007.... - Fatigue in multiple sclerosis: current understanding and future directionsSteven R Schwid
Department of Neurology, University of Rochester Medical Center, NY, USA
J Rehabil Res Dev 39:211-24. 2002..Dividing fatigue into these components can provide objective assessments that are less likely to be confounded by other symptoms of MS, such as weakness, spasticity, cognitive impairment, and depressed mood... - Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
Neurology 59:679-87. 2002..Studies of other IFNbeta preparations in secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNbeta-1a slowed disease progression in SP-MS... - Infections and MS: clinical trials move to center stageAndrew D Goodman
Neurology 58:7-8. 2002